SCHEMBL6848091

SCHEMBL6848091

CC(=O)Nc1ccc(S(=O)(=O)NC(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.77
GFER P55789 2/20 0.67
IDO1 P14902 4/20 0.65
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
GAA P10253 1/20 0.59
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
MMP1 P03956 1/20 0.58
MMP2 P08253 1/20 0.58
MMP9 P14780 1/20 0.58
MMP8 P22894 1/20 0.58
MMP13 P45452 1/20 0.58
ADAMTS4 O75173 1/20 0.58
ALDH1A1 P00352 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
SCN3A Q9NY46 1/20 0.55
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7908701 0.80 POLB (0.68) POLBGFERMEN1KMT2ACA1
SCHEMBL3402411 0.78 MEN1 (0.91) GFERIDO1MEN1KMT2AGAA
SCHEMBL27168770 0.78 ALDH1A1 (0.57) GFERMEN1KMT2AGAACA1
SCHEMBL5189116 0.77 MMP9 (0.76) POLBGFERMEN1KMT2AGAA
SCHEMBL12891199 0.77 POLB (0.60) POLBGFERIDO1MEN1KMT2A
SCHEMBL15871417 0.76 ALDH1A1 (0.56) GFERMEN1KMT2AGAACA1
SCHEMBL11700730 0.76 MEN1 (0.82) POLBGFERIDO1MEN1KMT2A
SCHEMBL14534640 0.76 PKM (0.74) POLBGFERIDO1MEN1KMT2A
SCHEMBL23611268 0.75 SCN3A (0.64) POLBGFERIDO1GAAALDH1A1
SCHEMBL23611270 0.75 SCN3A (0.64) POLBGFERIDO1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA POLB 2588/4885GFER 3157/4885IDO1 1394/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA POLB 2588/4885GFER 3157/4885IDO1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.